$ 49 / 10mg
999 in stock (can be backordered)
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that targets the ghrelin receptor (GHS-R1a) to stimulate pulsatile growth-hormone release from the anterior pituitary. It is one of the most potent GH secretagogues studied in preclinical research, producing robust and dose-dependent GH elevation in both in vitro and in vivo models. GHRP-2 peptide is widely used in endocrinology research examining GH-axis dynamics, appetite signaling, and metabolic regulation.
GHRP-2 peptide binds to GHS-R1a receptors, triggering intracellular calcium release and subsequent GH secretion. Unlike GHRH analogues that work through a separate receptor pathway, GHRP-2 also modestly stimulates ACTH and cortisol release — a pharmacological characteristic that distinguishes it from more selective secretagogues. In comparative studies, it has been shown to produce stronger GH pulses than GHRP-6, with less appetite stimulation.
GHRP-2 is commonly studied alongside Ipamorelin, a more selective GHS-R1a agonist with minimal cortisol effects, and Hexarelin, which offers the strongest GH-release potency in the GHRP family. Pairing with CJC-1295 (No DAC) enables dual GHRH + GHRP pathway research.
Each vial contains GHRP-2 peptide manufactured in the USA under ISO-certified conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
Lyophilized GHRP-2 peptide should be stored at -20°C in a sealed container protected from light and moisture to maintain long-term stability. For reconstitution, use bacteriostatic water and gently swirl the vial until the powder is fully dissolved — never shake, as this may degrade the peptide. Once reconstituted, store at 2–8°C (standard laboratory refrigeration) and use within 28 days. Aliquoting into single-use volumes is recommended for researchers conducting multiple experiments to minimize freeze-thaw cycles. Always use sterile technique when withdrawing from reconstituted vials. For research use only.
GHRP-2 was first synthesized in the early 1990s by Cyril Bowers and colleagues at Tulane University as part of systematic structure-activity studies on growth hormone-releasing peptides. It emerged from iterative modifications of Met-enkephalin derivatives, with researchers optimizing for GH-releasing potency through the ghrelin receptor pathway. Since its initial characterization, GHRP-2 has appeared in over 300 peer-reviewed publications indexed in PubMed, spanning endocrinology, pharmacology, and neuroendocrine research. Key institutions contributing to GHRP-2 literature include Tulane University, the Karolinska Institute, and the University of Virginia. Research groups have used GHRP-2 as a diagnostic tool for evaluating pituitary GH reserve, and it remains a reference compound in comparative secretagogue pharmacology studies. All research cited is from preclinical and laboratory settings.
GHRP-2 is a synthetic hexapeptide that stimulates growth-hormone release by binding the ghrelin receptor (GHS-R1a). It produces stronger GH pulses than GHRP-6 with less appetite stimulation, and has a modest cortisol-stimulating effect that distinguishes it from more selective options like Ipamorelin.
GHRP-2 peptide is used in preclinical studies examining GH-axis dynamics, pituitary function, appetite signaling, and comparative secretagogue pharmacology. It is frequently paired with GHRH analogues like CJC-1295 for dual-pathway GH research.
Each vial is manufactured in the USA under ISO-certified conditions, verified to ≥99% purity by HPLC analysis, with endotoxin levels screened below 0.1 EU/mg. A Certificate of Analysis (COA) is available upon request. For laboratory and research use only.
